CTLA4 and endocrine system disorder: Notably, autoimmune diabetes exhibits near–exclusive association with PD-1/PD-L1 inhibitors (either as monotherapy or in combination), with minimal occurrence following CTLA-4 inhibitor monotherapy (19), highlighting the distinct immunological mechanisms underlying different ICI-associated endocrinopathies.